Skip to content
Menu

Humacyte Submits sBLA To FDA For Acellular Tissue Engineered Vessel Seeking Approval In Arteriovenous Access For Hemodialysis In Patients With End-Stage Kidney Disease

Benzinga Newsdesk 8 hours ago

News

–sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV.–sBLA supported by results from three Phase 3 studies in hemodialysis access.–"For too long, patients on

–sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV.

–sBLA supported by results from three Phase 3 studies in hemodialysis access.

–"For too long, patients on dialysis, and women in particular, have had to settle for access options that often do not work well for them. We are excited about the potential of the ATEV to provide a new potential vascular access option for hemodialysis patients in need," said Laura Niklason, M.D., Ph.D., Co-Founder and Chief Executive Officer of Humacyte.

DURHAM, N.C., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the acellular tissue engineered vessel (ATEV) seeking approval in arteriovenous (AV) access for hemodialysis in patients with end-stage kidney disease (ESKD) who are at an increased risk of AV fistula maturation failure. The sBLA seeks to add hemodialysis access as the second approved indication for the ATEV following the FDA approval of the ATEV under the brand name Symvess® in December 2024 for the extremity vascular trauma indication.

Read at benzinga.com